Prospective, Randomized Trial of Personalized Medicine With Pentaglobin® After Surgical Infectious Source Control in Patients With Peritonitis
Key facts
- Who runs it
- RWTH Aachen University
- Where
- Austria and Germany13 sites in 2 countriesChoose a country to see its sites
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 200 people, planned
- Started
- 20 Nov 2017
- Expected to end
- Mar 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Pentaglobin®/Standard of Care
- Record updated
- 11 June 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (17)Hide the full registry criteria
Who can take part
- The patient is diagnosed with secondary or quaternary peritonitis
- The time of the surgical infectious source control is within 6 hours of indication (defined as date and time of registration for surgical or minimal invasive procedure)
- Sepsis and / or septic shock (according to the current sepsis guideline of the German Sepsis Society)
- SOFA Score ≥ 8
- The concentration of IL-6 is ≥ 1000 pg / ml
- Treatment with antibiotics is started within 12 hours of admission to the Intensive Care Unit
- The informed consent form has been signed by the patient and / or by his legal representative (such as his spouse, an health care proxy authorized or a legal representative) or by a consultant physician
Who cannot take part
- The patient has any contraindication to study drug
- Patients with a life expectancy of less than 90 days due to medical conditions unrelated to peritonitis nor with sepsis and / or septic shock
- The patient has known chronic renal dysfunction requiring dialysis (creatinine ≥ 3.4 mg / dl or creatinine clearance ≤ 30 mL/min/1.73 m²)
- The patient is a minor (< 18 years of age)
- For female patients: The patient is pregnant or breastfeeding
- The patient has acute, primarily non-infectious pancreatitis or mediastinitis
- The patient has a BMI > 40
- The patient has participated in another clinical trial within the last 30 days
- The patient is in a dependent or employment relationship with the sponsor or investigator
- The patient is institutionalized by court or government order
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Peritonitis or sepsis or septic shock
This trial is currently available in Austria and Germany.
It has sites in 2 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
The aim of this prospective, randomized, controlled trial is to provide evidence for adjuvant IgGAM treatment with regard to
Read full original descriptionShow less
1. Improvement of patient outcomes for peritonitis. Improvement in outcome will be determined by scores such as MOF, SOFA and survival. 2. Identification of biomarkers (including immunoglobulin levels, HLA-DR, NF-kB1 and other immunological biomarkers) to identify patient subpopulations that benefit most from IgGAM treatment. These patients will form the basis for a further randomized, controlled, double-blind Phase III trial (RCT) to demonstrate the benefit of this treatment. 3. In addition, these biomarkers could help to guide a targeted, i.e. "personalized", adjuvant therapy with Pentaglobin® (IgGAM) in the indication of peritonitis.
The 2 groups in the trial
- Control armNo study treatment, for comparison
Standard of Care treatment
- Verum armExisting treatment, for comparison
Standard of Care treatment + Pentaglobin®
Treatment: Pentaglobin®/Standard of Care
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Criteria questions
- Built from NCT03334006, who can take part
- Publications
- Record updated
- 11 June 2026